289 related articles for article (PubMed ID: 24646176)
21. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
[TBL] [Abstract][Full Text] [Related]
22. Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.
Friedman GK; Moore BP; Nan L; Kelly VM; Etminan T; Langford CP; Xu H; Han X; Markert JM; Beierle EA; Gillespie GY
Neuro Oncol; 2016 Feb; 18(2):227-35. PubMed ID: 26188016
[TBL] [Abstract][Full Text] [Related]
23. Treatment of medulloblastoma with a modified measles virus.
Studebaker AW; Kreofsky CR; Pierson CR; Russell SJ; Galanis E; Raffel C
Neuro Oncol; 2010 Oct; 12(10):1034-42. PubMed ID: 20494960
[TBL] [Abstract][Full Text] [Related]
24. A recombinant measles virus vaccine strain rMV-Hu191 has oncolytic effect against human gastric cancer by inducing apoptotic cell death requiring integrity of lipid raft microdomains.
Lv Y; Zhou D; Hao XQ; Zhu MY; Zhang CD; Zhou DM; Wang JH; Liu RX; Wang YL; Gu WZ; Shen HQ; Chen X; Zhao ZY
Cancer Lett; 2019 Sep; 460():108-118. PubMed ID: 31226409
[TBL] [Abstract][Full Text] [Related]
25. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.
Iankov ID; Allen C; Federspiel MJ; Myers RM; Peng KW; Ingle JN; Russell SJ; Galanis E
Mol Ther; 2012 Jun; 20(6):1139-47. PubMed ID: 22334023
[TBL] [Abstract][Full Text] [Related]
26. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.
Jing Y; Zaias J; Duncan R; Russell SJ; Merchan JR
Gene Ther; 2014 Mar; 21(3):289-97. PubMed ID: 24430235
[TBL] [Abstract][Full Text] [Related]
27. Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer.
Tysome JR; Briat A; Alusi G; Cao F; Gao D; Yu J; Wang P; Yang S; Dong Z; Wang S; Deng L; Francis J; Timiryasova T; Fodor I; Lemoine NR; Wang Y
Gene Ther; 2009 Oct; 16(10):1223-33. PubMed ID: 19587709
[TBL] [Abstract][Full Text] [Related]
28. The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF.
Dey A; Zhang Y; Castleton AZ; Bailey K; Beaton B; Patel B; Fielding AK
Mol Ther; 2016 Feb; 24(1):184-92. PubMed ID: 26278331
[TBL] [Abstract][Full Text] [Related]
29. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Jing Y; Bejarano MT; Zaias J; Merchan JR
Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
[TBL] [Abstract][Full Text] [Related]
30. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.
Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW
BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685
[TBL] [Abstract][Full Text] [Related]
31. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
32. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
[No Abstract] [Full Text] [Related]
33. Measles virus for cancer therapy.
Russell SJ; Peng KW
Curr Top Microbiol Immunol; 2009; 330():213-41. PubMed ID: 19203112
[TBL] [Abstract][Full Text] [Related]
34. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus.
Allagui F; Achard C; Panterne C; Combredet C; Labarrière N; Dréno B; Elgaaied AB; Pouliquen D; Tangy F; Fonteneau JF; Grégoire M; Boisgerault N
Curr Gene Ther; 2017; 16(6):419-428. PubMed ID: 28042780
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.
Li H; Peng KW; Russell SJ
Hum Gene Ther; 2012 Mar; 23(3):295-301. PubMed ID: 22235810
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.
Msaouel P; Iankov ID; Allen C; Aderca I; Federspiel MJ; Tindall DJ; Morris JC; Koutsilieris M; Russell SJ; Galanis E
Mol Ther; 2009 Dec; 17(12):2041-8. PubMed ID: 19773744
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic measles viruses for cancer therapy.
Nakamura T; Russell SJ
Expert Opin Biol Ther; 2004 Oct; 4(10):1685-92. PubMed ID: 15461580
[TBL] [Abstract][Full Text] [Related]
38. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.
Zhang W; Fulci G; Wakimoto H; Cheema TA; Buhrman JS; Jeyaretna DS; Stemmer Rachamimov AO; Rabkin SD; Martuza RL
Neoplasia; 2013 Jun; 15(6):591-9. PubMed ID: 23730207
[TBL] [Abstract][Full Text] [Related]
39. Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.
Kaufmann JK; Bossow S; Grossardt C; Sawall S; Kupsch J; Erbs P; Hassel JC; von Kalle C; Enk AH; Nettelbeck DM; Ungerechts G
J Invest Dermatol; 2013 Apr; 133(4):1034-42. PubMed ID: 23223133
[TBL] [Abstract][Full Text] [Related]
40. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.
Yu L; Baxter PA; Zhao X; Liu Z; Wadhwa L; Zhang Y; Su JM; Tan X; Yang J; Adesina A; Perlaky L; Hurwitz M; Idamakanti N; Police SR; Hallenbeck PL; Blaney SM; Chintagumpala M; Hurwitz RL; Li XN
Neuro Oncol; 2011 Jan; 13(1):14-27. PubMed ID: 21075780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
